regulatory
confidence high
sentiment neutral
materiality 0.55
Entero Therapeutics provides latiglutenase Phase 3 plan, FDA meetings, $1.9M raise
GridAI Technologies Corp.
- Submits Type D requests to FDA to streamline Phase 3 trial cohorts from three to two (1200 mg and placebo).
- Second Type D request seeks FDA agreement on histology secondary endpoints based on Phase 2 results.
- Raised $1.9 million in gross proceeds from a small financing to support Phase 3 trial initiation.
- Consolidated bi-coastal operations into Boca Raton HQ to reduce overhead costs.
- CEO James Sapirstein reaffirms goal to start pivotal Phase 3 trial for latiglutenase in 2025.